Flush With CF Success, Vertex Prepares Next-Gen Pipeline For Busy 2023

Sickle Cell Therapy Could Be Approved Next Year

 
• By Andrew McConaghie

Vertex’s dominance in cystic fibrosis looks secure for years to come, and 2023 and 2024 could see it bring more ground-breaking innovation to market.

Vertex Mobile
Vertex shares are up 35% so far this year, making it one of the sector's top mid-sized performers. • Source: Shutterstock

More from Earnings

More from Business